An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin

Platelet adhesion and signaling depend on integrin receptors. These receptors are heterodimeric glycoproteins that bind extracellular matrix proteins. Researchers have identified several integrins, but their specific roles in thrombospondin binding remain unclear. Prior work has shown that thrombospondin interacts with cell surfaces via RGD-dependent mechanisms. However, the precise integrin responsible for this interaction in platelets is not fully characterized. This uncertainty drives the need for more detailed receptor mapping. Some studies suggest that multiple integrins may bind thrombospondin. But no prior work had resolved the specific integrin subtypes involved in platelet interactions. This gap motivated the current investigation into platelet integrin function.

This study aimed to identify integrins on human platelets that bind thrombospondin. The researchers focused on two integrins: GPIIb-IIIa and alpha v beta 3. They wanted to determine how these receptors interact with thrombospondin. The study also sought to compare receptor levels in normal and thrombasthenic platelets. Researchers used radiolabeling and affinity chromatography to isolate integrins. They tested whether GRGDSP could elute bound integrins from thrombospondin. The goal was to confirm RGD-dependent binding mechanisms. This work addresses a specific problem in integrin function research.

The researchers radiolabeled platelet membrane proteins using 125I-lactoperoxidase. They solubilized the proteins in n-octylglucoside and applied them to thrombospondin-Sepharose. Bound integrins were eluted with the GRGDSP peptide. This method allowed specific isolation of thrombospondin-binding integrins. The team used monoclonal antibody LM142 to identify alpha v subunits. They compared alpha v beta 3 levels in normal and thrombasthenic platelets. The study also assessed fibrinogen, vitronectin, and vWF binding. These tools helped distinguish between integrin subtypes and their functions.

Two integrins bound thrombospondin: GPIIb-IIIa and alpha v beta 3. GPIIb-IIIa showed weak binding, while alpha v beta 3 bound more strongly. Both were eluted with GRGDSP, confirming RGD-dependent interactions. Alpha v beta 3 shared the beta 3 subunit but had a distinct alpha subunit. This alpha subunit comigrated with vitronectin receptor alpha v. The LM142 antibody reacted specifically with alpha v beta 3. Levels of alpha v beta 3 were similar in normal and thrombasthenic platelets. Thrombasthenic platelets still bound thrombospondin via alpha v beta 3.

The study supports the role of alpha v beta 3 as an RGD-dependent thrombospondin receptor. This integrin functions similarly on platelets, endothelial, and smooth muscle cells. The findings clarify the receptor mechanism for thrombospondin binding. The data suggest that alpha v beta 3 is not reduced in thrombasthenic platelets. This integrin may also bind fibrinogen, vitronectin, and vWF. The results align with prior observations in endothelial and melanoma cells. The study does not propose new drug targets or future directions. The authors emphasize the importance of RGD motifs in integrin function.